White label – Pompe disease - ClinicalTrials.eu

Study on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors

Not recruiting

1 1 1 1
Investigated Diseases:
Investigated Drugs:
- Nivolumab
- Relatlimab
+3
Study comparing brigatinib alone versus brigatinib with carboplatin and pemetrexed combination as first treatment for patients with advanced ALK-positive lung cancer

Not recruiting

2 1 1 1
Investigated Diseases:
- Non-small cell lung cancer stage IIIB
- Non-small cell lung cancer stage IV
Investigated Drugs:
Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

Not recruiting

3 1
Investigated Diseases:
- Squamous cell carcinoma of head and neck
Investigated Drugs:
- Xevinapant
+6
Study of Palbociclib as an Alternative to Chemotherapy for Older Patients with High-Risk Early Breast Cancer

Not recruiting

2 1 1 1
Investigated Diseases:
- Hormone receptor positive breast cancer
Investigated Drugs:
+1
Long-Term Safety Study of Riliprubart in Patients with Cold Agglutinin Disease

Not recruiting

1 1 1
Investigated Diseases:
- Autoimmune haemolytic anaemia
Investigated Drugs:
- Riliprubart
Study of Nivolumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Not recruiting

3 1 1
Investigated Diseases:
- Hepatocellular carcinoma
Investigated Drugs:
- Nivolumab
+2
Study on Talquetamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Not recruiting

2 1 1 1
Investigated Drugs:
- Talquetamab
- Tocilizumab
Study of pembrolizumab and vorinostat combination therapy in patients with recurrent or metastatic squamous cell carcinoma of head and neck, cervix, anus, and genital areas

Not recruiting

2 1 1 1
Investigated Diseases:
Investigated Drugs:
- Vorinostat
- Pembrolizumab
Study on the Effectiveness and Safety of Crovalimab for Children with Atypical Hemolytic Uremic Syndrome (aHUS)

Not recruiting

3 1 1
Investigated Drugs:
- Crovalimab
Study on the Effectiveness of Autogene Cevumeran in Patients with ctDNA Positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Not recruiting

2 1
Investigated Diseases:
- Colorectal cancer stage III
Investigated Drugs:
- Autogene Cevumeran

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies